CoChat

Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans

Open access
Gómez-Banoy, Nicolás, Guseh, J. Sawalla, Li, Ge, Rubio-Navarro, Alfonso, Chen, Tong, Poirier, BreAnne, Putzel, Gregory, Rosselot, Carolina, Pabón, Maria A., Camporez, João Paulo, Bhambhani, Vijeta, Hwang, Shih-Jen, Yao, Chen, Perry, Rachel J., Mukherjee, Sushmita, Larson, Martin G., Levy, Daniel, Dow, Lukas E., Shulman, Gerald I., Dephoure, Noah, Garcia-Ocana, Adolfo, Hao, Mingming, Spiegelman, Bruce M., Ho, Jennifer E., Lo, James C. · 2019 · Nature Medicine
Cited by 178

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes is characterized by insulin resistance and a gradual loss of pancreatic beta cell mass and function1,2. Currently, there are no therapies proven to prevent beta cell loss and some, namely insulin secretagogues, have been linked to accelerated beta cell failure, thereby limiting their use in type 2 diabetes3,4. The adipokine adipsin/complement factor D controls the alternative complement pathway and generation of complement component C3a, which acts to augment beta cell insulin secretion5. In contrast to other insulin secretagogues, we show that chronic replenishment of adipsin in diabetic db/db mice ameliorates hyperglycemia and increases insulin levels while preserving beta cells by blocking dedifferentiation and death. Mechanistically, we find that adipsin/C3a decreases the phosphatase Dusp26; forced expression of Dusp26 in beta cells decreases expression of core beta cell identity genes and sensitizes to cell death. In contrast, pharmacological inhibition of DUSP26 improves hyperglycemia in diabetic mice and protects human islet cells from cell death. Pertaining to human health, we show that higher concentrations of circulating adipsin are associated with a significantly lower risk of developing future diabetes among middle-aged adults after adjusting for body mass index (BMI). Collectively, these data suggest that adipsin/C3a and DUSP26-directed therapies may represent a novel approach to achieve beta cell health to treat and prevent type 2 diabetes. Targeting the adipokine adipsin and its downstream pathway may provide an approach for preservation of beta cell loss in type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0610-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Metadata

Authors
Gómez-Banoy, N., Guseh, J. S., Li, G., Rubio-Navarro, A., Chen, T., Poirier, B., Putzel, G., Rosselot, C., Pabón, M. A., Camporez, J. P., Bhambhani, V., Hwang, S.-J., Yao, C., Perry, R. J., Mukherjee, S., Larson, M. G., Levy, D., Dow, L. E., Shulman, G. I., Dephoure, N., Garcia-Ocana, A., Hao, M., Spiegelman, B. M., Ho, J. E., & Lo, J. C.
Venue
Nature Medicine
Published
2019-11
Volume
25
Issue
11
Pages
1739-1747
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2985194635
Cited by
178
References
26
FWCI
16.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. https://app.cochat.ai/papers/10.1038/s41591-019-0610-4
The paper
Gómez-Banoy, N., Guseh, J. S., Li, G., Rubio-Navarro, A., Chen, T., Poirier, B., Putzel, G., Rosselot, C., Pabón, M. A., Camporez, J. P., Bhambhani, V., Hwang, S.-J., Yao, C., Perry, R. J., Mukherjee, S., Larson, M. G., Levy, D., Dow, L. E., Shulman, G. I., . . . Lo, J. C. (2019). Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nature Medicine. https://doi.org/10.1038/s41591-019-0610-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.